Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD)

A Single-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Phase IIa Study to Investigate the Effects of 100mg AZD2423 as an Oral Tablet in Subjects With Mild COPD Following Segmental Endobronchial LPS Instillation

The purpose of the study is to find out if AZD2423 can reduce inflammation in the lungs of patients with mild COPD.

Inclusion Criteria:

• Only women of non-child bearing potential are included in the study i.e. women who are permanently or surgically sterilised or post menopausal.
• ≥ 40 years of age at Visit 1
• Clinical diagnosis of COPD (GOLD stage 1)
• FEV1 ≥ 80% of the predicted normal post-bronchodilator at Visit 1 (GOLD stage 1)
• FEV1/FVC <70% post-bronchodilator at Visit 1 (GOLD stage 1)

Exclusion Criteria:

• Any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk or influence the way the drug works
• Any clinically relevant abnormal findings in physical examination, blood or urine test results, vital signs or ECG at Visit 1 that may put the subject at risk during the study, affect their ability or take part or influence the results of the study
• A past history or current indication of renal (kidney) failure
• Subjects at risk of active tuberculosis or of disease reactivation
• Subjects who have had any clinically significant illness within 4 weeks before Visit 2 (start of treatment)